GNOSPV-01 is under clinical development by Geneos Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GNOSPV-01’s likelihood of approval (LoA) and phase transition for Hormone-Sensitive Prostate Cancer took place on 08 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GNOSPV-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GNOSPV-01 overview

GNOSPV-01 is under investigation for the prevention of recurrent brain tumor, metastatic hormone-sensitive prostate cancer, triple negative breast cancer, glioblastoma multiforme, non-small cell lung cancer, adenocarcinoma of pancreatic cancer and follicular lymphoma. Personalized peptide vaccination identifies the specific peptides that mark the tumor as dangerous and reintroduce them in increased concentration to the immune system via vaccination. It is administered through subcutaneous and intramuscular route. The vaccine candidate was also under development for renal cell carcinoma.

Geneos Therapeutics overview

Geneos Therapeutics, is a biopharmaceutical company that develops neoantigen targeting cancer immunotherapies. The company is headquartered in United States.

Quick View GNOSPV-01 LOA Data

Report Segments
  • Innovator
Drug Name
  • GNOSPV-01
Administration Pathway
  • Intramuscular
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.